BridgeBio Pharma Inc. terminated its bid for the remaining stake in Eidos Therapeutics Inc. as it failed to reach an agreement with a special committee of Eidos' board.

Palo Alto, Calif.-based BridgeBio, which develops therapies for genetic diseases, owns about 66% stake in Eidos. The company's final offer was equivalent to 1.5 BridgeBio shares for each Eidos share.

Initially, BridgeBio offered 1.3 shares for each Eidos share. A special committee of Eidos board unanimously rejected the offer in September.

Under the offer, Eidos' shareholders had the option to choose between receiving their consideration as all-stock, cash and stock mix, or all-cash, such that the transaction is not more than $110 million.

San Francisco-based biotechnology company Eidos develops treatments for a progressive condition associated with the buildup of abnormal deposits of a certain protein called amyloid in the organs and tissues.

Eidos' stock price was down 6.7% to $36.01 as of 1:43 p.m. on Oct. 14.